Narcolepsy type 1 (NT1) is a rare disorder affecting roughly 200 to 500 people per million, caused by the selective loss of orexin-producing neurons in the brain. Orexin, also called hypocretin, is a neuropeptide system that stabilizes wakefulness, and its loss produces the disorder’s hallmark symptoms: overwhelming daytime sleepiness, fragmented nighttime sleep, cataplexy, sleep paralysis, and vivid hypnagogic hallucinations. Narcolepsy type 2 (NT2) shares most of these symptoms but lacks cataplexy and typically shows normal orexin levels in cerebrospinal fluid, leaving its underlying biology poorly understood. Beyond the classic symptom pentad, patients frequently carry comorbidities including obesity, obstructive sleep apnea, depression, and autonomic dysfunction, and many report chronic pain syndromes such as migraine and lower back pain.

The review, which followed PRISMA systematic review guidelines, compiled clinical and mechanistic literature on chronic pain in narcolepsy. The numbers are striking. Cross-sectional studies report chronic pain prevalence estimates ranging from 32.8 to 84.84 percent in narcolepsy, depending on how pain is defined, whether as pain occurring at least monthly or as pain lasting three months or longer. Observational studies and a community-based cohort, with sample sizes between 66 and 2,057 participants, all found increased pain-related comorbidity. In one study that included both subtypes, 84.84 percent of NT1 patients and 75.75 percent of NT2 patients reported chronic pain.

One particularly revealing finding concerns how pain is perceived by others. When researchers compared patients’ self-reported pain with assessments made by close acquaintances and by physicians, 83 percent of the acquaintances’ evaluations aligned closely with the patients’ own reports. Physicians, however, significantly underestimated pain severity in 60 percent of cases, a statistically significant discrepancy that the authors say reinforces the need for greater clinical awareness of pain in this population.

A central question is whether the pain can be attributed to comorbidities alone. Mood disorders and disturbed sleep are known to influence pain perception, and narcolepsy patients carry a heavy burden of both. To address this, one study used propensity score matching, controlling not only for demographics but for the total number of diagnoses, improving comparability between narcolepsy patients and controls. Even after this adjustment, chronic pain remained significantly more prevalent in the narcolepsy group, suggesting that measured comorbidities do not fully explain the association, although the authors caution that residual confounding cannot be excluded. Population-level data add weight to the synergy hypothesis: depression and sleep disorders each raise chronic pain risk individually, but their combined effect nearly quadruples it, with an odds ratio of 3.95 for chronic low back pain.

Yet when researchers measure pain sensitivity directly, the picture changes dramatically. Quantitative sensory testing in a small NT1 cohort of 13 patients and 13 matched controls found no significant differences in mechanical, cold, warm, or pressure pain thresholds, even though sleepiness was measured and matched between groups. A larger follow-up study of 39 NT1 patients assessing muscle pain sensitivity and temporomandibular disorders likewise found no experimental differences, and notably, those patients did not show elevated chronic pain questionnaire scores, possibly because exclusion criteria removed individuals with pain-affecting conditions, making the sample unrepresentative of the broader NT1 population. The authors conclude that experimental thresholds capture only specific aspects of nociceptive processing and may not reflect the mechanisms driving chronic pain in daily life.

Several mechanistic hypotheses emerge from the review. The near-equal pain prevalence in NT1 and NT2 weakens the argument that orexin deficiency alone drives pain in NT1. However, cerebrospinal fluid measurements may be misleading: conventional assays cannot distinguish intact, biologically active orexin peptides from inactive degradation products. In some NT1 patients initially classified as non-deficient, the fraction of intact orexin was significantly lower than in controls, and NT2 patients showed a non-significant trend toward lower intact orexin. Subtle dysfunction could therefore hide behind seemingly normal concentrations.

The orexin system’s role in pain is genuinely two-sided. Orexin A acts predominantly through the OX1 receptor, whose signaling in the periaqueductal gray supports analgesia, so its loss in NT1 may weaken an important inhibitory pathway. Orexin B binds the OX2 receptor with tenfold greater affinity, and OX2 receptor activation can mediate either pro- or antinociceptive effects depending on context and brain region. Recent animal work suggests orexin B may protect against neuropathic pain by suppressing neuroinflammation and oxidative stress, while other findings indicate OX2 activation can promote nociception under stress-related or inflammatory conditions. With both orexin neuropeptides severely depleted in NT1, the delicate balance between anti- and pronociceptive signaling could tip toward heightened pain perception, potentially explaining why patients show such varied pain profiles.

Another candidate mechanism lies downstream of orexin: dopamine. Orexin neurons innervate dopaminergic regions such as the ventral tegmental area and promote dopamine release in the nucleus accumbens, and the dopaminergic system is involved in both arousal and pain inhibition. Orexin loss in NT1 may therefore impair dopaminergic tone, contributing not only to sleep-wake instability but to altered pain processing. Intriguingly, a case report describes a narcolepsy patient whose chronic migraine resolved with armodafinil, a wake-promoting drug that raises extracellular dopamine by blocking reuptake, with the benefit sustained for over a year and pain returning only after discontinuation. The headache improvement coincided with reduced fatigue, hinting at a shared dopaminergic mechanism, though controlled studies have not yet confirmed this.

A final, more speculative thread involves the immune system. A case series of ten NT1 patients found activating autoantibodies against G-protein-coupled nociceptive receptors in 90 percent of patients, compared with none of 100 healthy controls, a difference the authors describe as statistically striking but based on limited evidence. If these antibodies functionally alter nociceptive signaling, an immune-mediated component of pain in some patients becomes plausible, though functional assays are needed to establish this. Taken together, the review concludes that chronic pain in narcolepsy is best understood as a multifactorial phenomenon shaped by disease biology, disturbed sleep, fatigue, and mood symptoms interacting with one another. The clinical implication is clear: physicians should not rely on targeted pharmacology alone but should address depression, sleep disturbance, and fatigue in parallel with pain, and future studies should improve case-control matching, include larger NT1 samples enriched for chronic pain, and compare subtypes more rigorously.

Subject of Research: Chronic pain mechanisms in narcolepsy type 1 and type 2

Article Title: Chronic pain in narcolepsy reflects interacting neurobiological and psychological mechanisms: a mini-review

Article References: Chronic pain in narcolepsy reflects interacting neurobiological and psychological mechanisms: a mini-review. (n.d.). https://doi.org/10.3389/frsle.2026.1930803

Image Credits: AI Generated

DOI: 10.3389/frsle.2026.1930803

Keywords: narcolepsy, chronic pain, orexin, hypocretin, dopamine, autoantibodies, sleep disorders, depression, quantitative sensory testing, OX1 receptor, OX2 receptor, narcolepsy type 2

Orexin-A, also known as hypocretin-1, is best known to sleep scientists as the molecule whose loss causes narcolepsy. But its repertoire extends far beyond keeping animals awake. The peptide binds two G-protein-coupled receptors, OX1R and OX2R, distributed across brain regions that govern arousal, autonomic tone, and stress responses. In experimental models of cerebral hypoxia-ischemia, orexin signaling has repeatedly shown neuroprotective properties, apparently acting through pathways that include hypoxia-inducible factor 1-alpha, the master transcriptional switch that cells deploy when oxygen runs low. This dual identity, as both a sleep regulator and a stress-response molecule, made orexin-A an intriguing target for researchers hunting for a window into the injured newborn brain. If the peptide’s concentration in blood reflected the brain’s struggle to cope with oxygen deprivation, it might serve as a real-time reporter of neurological status in a way that static measures of tissue damage cannot.

The research team, led by pediatric neurologists Pınar Gençpınar and Gunce Basarir and spanning multiple institutions in İzmir and Istanbul, Türkiye, enrolled forty-one newborns born at thirty-six weeks of gestation or later, all diagnosed with HIE within the first six hours after birth. The design was deliberately longitudinal: blood samples were drawn twice, once between six and twelve hours of life and again between seventy-two and ninety-six hours, capturing the earliest window in which clinicians must make decisions and the period immediately after cooling ends. Twenty-two of the infants underwent therapeutic hypothermia according to standard criteria, while nineteen, whose severity did not meet cooling thresholds or for whom cooling was not indicated, were managed with supportive normothermic care. Serum orexin-A concentrations were quantified using enzyme-linked immunosorbent assay, and the researchers cross-referenced the peptide’s behavior with an unusually rich clinical dataset: amplitude-integrated electroencephalography, conventional video EEG, brain magnetic resonance imaging, and routine metabolic indices.

The headline finding is subtle but striking. At neither time point did absolute orexin-A concentrations differ significantly between the cooled and non-cooled groups, a result that on its own might have seemed like a dead end for the biomarker hypothesis. The story emerged only when the researchers examined each infant’s trajectory over time. Among babies who received therapeutic hypothermia, orexin-A levels were relatively preserved or even rose between the two measurements, with a median within-subject change of plus 31.2 picograms per milliliter. Among babies managed without cooling, the peptide fell sharply, with a median change of minus 54.5 picograms per milliliter. The difference between these trajectories was statistically robust, with a p-value of 0.002, and significantly more infants in the hypothermia group showed a higher value at the second sampling than at the first. In the normothermia group, the decline over time was itself significant, at p equal to 0.005.

What makes this pattern scientifically interesting is that it inverts the usual logic of injury biomarkers. Molecules such as neuron-specific enolase, glial fibrillary acidic protein, neurofilament light chain, and ubiquitin C-terminal hydrolase-L1 are released when cells die, so higher concentrations generally signal worse damage. Orexin-A appears to behave differently. The authors interpret it as a marker of functional state rather than tissue injury: a brain that is still actively regulating arousal, autonomic function, and stress responses keeps producing and releasing orexin, while a more profoundly depressed brain lets circulating levels drift downward. The longitudinal change also differed significantly by amplitude-integrated EEG background, with a p-value of 0.010, suggesting that the peptide’s trajectory carries electrophysiological meaning. However, the researchers note an important caveat here: abnormal EEG tracings were almost entirely confined to the hypothermia group, which complicates any attempt to disentangle the peptide’s relationship with brain function from the effects of illness severity itself.

Indeed, the study is unusually candid about its central limitation. Treatment allocation in HIE is inseparable from disease severity, because cooling is prescribed precisely for the sickest infants. The preserved or rising orexin-A trajectories seen under hypothermia therefore cannot be attributed to cooling itself; they may simply reflect that cooled infants, despite being more severely affected, occupied a different physiological regime, or that the interplay between severity and treatment produced the observed divergence. The authors explicitly state that these trajectories cannot be ascribed to the cooling intervention, a level of interpretive restraint that is rare and welcome in biomarker research. Similarly, higher concentrations at the second time point tracked clinical severity only in outlier-sensitive statistical analyses, hinting that a small number of extreme values may have driven part of the apparent signal, and that the peptide’s relationship with severity is weaker and less linear than a simple biomarker model would predict.

Equally informative are the relationships that failed to materialize. Neither the absolute concentrations nor the longitudinal changes of orexin-A correlated with video EEG findings, with abnormalities on brain MRI, or with routine metabolic indices. This null pattern reinforces the idea that orexin-A is not reporting on structural damage. MRI lesions and epileptiform discharges reflect injury to neural tissue, whereas the peptide’s trajectory seems to reflect something closer to the brain’s ongoing regulatory activity. If this distinction holds up in future work, it would position orexin-A as a complementary rather than redundant marker, one that could in principle answer a question that damage markers cannot: not how much brain has been lost, but how much functional capacity remains and how it is evolving hour by hour.

The technical execution of the study deserves attention as well. Measuring orexin-A reliably in neonatal serum is demanding, since the peptide is present at low concentrations and ELISA-based assays are sensitive to pre-analytical handling. The two-sample design, anchored to clinically meaningful windows, allowed the researchers to compute within-subject changes, which are far more informative than cross-sectional comparisons in a condition as dynamic as HIE. The study was funded by the Scientific and Technological Research Council of Türkiye under its 1002 support module, and the results were previously presented at the fifteenth Congress of the European Paediatric Neurology Society in Prague in June 2023, indicating that the findings have circulated through the specialist community before formal publication.

For clinicians and families, the practical message for now is one of tempered promise. Orexin-A is not ready for the neonatal intensive care unit. The authors are explicit that serial sampling in larger, severity-matched cohorts, ideally with long-term neurodevelopmental follow-up, is required before any clinical role can be defined. Such studies would need to disentangle the effects of cooling from the effects of severity, perhaps by comparing infants with matched severity who did and did not receive cooling, or by tracking orexin-A in animal models where treatment can be randomized. They would also need to establish whether the trajectory of the peptide predicts outcomes such as cerebral palsy, cognitive impairment, or epilepsy, which is the endpoint that ultimately matters to families.

Still, the conceptual contribution of this work may prove durable. In a field dominated by markers of destruction, a molecule that reports on the brain’s living regulatory activity offers a genuinely different lens on neonatal brain injury. The finding that the direction of change, rather than any single concentration, carries the signal is a methodological lesson that extends beyond orexin-A: biomarkers of dynamic physiological states may only reveal their value when sampled repeatedly and interpreted as trajectories. As the search for clinically usable biomarkers in HIE continues, this small Turkish study of forty-one newborns adds a compelling hypothesis to the pipeline, and a reminder that in the injured newborn brain, the most telling numbers may be the ones that move.

Subject of Research: Serum orexin-A dynamics in neonatal hypoxic-ischemic encephalopathy and therapeutic hypothermia

Article Title: Temporal profile of serum orexin-A in neonatal hypoxic-ischemic encephalopathy: a prospective longitudinal study

Article References: Gençpınar, P., Basarir, G., Ersen, A., Engür, D., Olgaç Dündar, N., Üstün, H., Kefeli Demirel, M., Sarıoğlu, F. C., & İşbilen Başok, B. (2026). Temporal profile of serum orexin-A in neonatal hypoxic-ischemic encephalopathy: a prospective longitudinal study. BMC Pediatrics, 26(1), Article 968. https://doi.org/10.1186/s12887-026-07727-0

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07727-0

Keywords: orexin-A, hypoxic-ischemic encephalopathy, therapeutic hypothermia, biomarker, newborn, hypothalamus, neuropeptide, electroencephalography, brain MRI, neonatology, neuroprotection, hypocretin

At the heart of the exchange is a question that has long troubled sleep researchers: how do you study mortality in a disease as rare as narcolepsy without waiting decades for a prospective cohort to mature? Narcolepsy affects roughly one in two thousand people, and its two main forms, narcolepsy type 1 with cataplexy and narcolepsy type 2 without cataplexy, are distinguished by features that require specialized testing to confirm. The authors argue that for rare conditions, electronic health record based cohort studies remain indispensable precisely because the prospective designs their critics favor are seldom feasible at the scale or duration needed to detect mortality signals. Their study leveraged the Veterans Health Administration’s longitudinal records, which follow patients across decades of care, offering a follow-up window of 25 years that no single-center prospective study could realistically match.

One of the sharpest criticisms concerned bias. Mehri and Finsterer invoked limitations commonly associated with retrospective designs, including recall bias, selection bias, and confounding. The authors’ reply draws a technical distinction here that is worth unpacking. Recall bias, the distortion that arises when patients or investigators remember exposures imperfectly, is a meaningful threat in studies that rely on interviews or chart reviews conducted after the fact. It is not, however, a meaningful threat in administrative electronic health record cohorts, where exposures and outcomes are recorded prospectively at the point of care, independent of anyone’s memory. A diagnosis code entered during a clinic visit and a death recorded in a vital status file are not subject to the fallibilities of recollection. Selection bias and confounding, by contrast, the authors concede, remain legitimate concerns in any observational dataset, and they describe the specific countermeasures they deployed.

Those countermeasures centered on propensity score matching, a statistical technique widely used in non-randomized research to approximate the balance achieved in randomized trials. In the narcolepsy study, patients with narcolepsy were matched to comparator patients from general sleep clinics on age, sex, race and ethnicity, and index diagnosis year, with additional adjustment for body mass index and the Charlson Comorbidity Index, a validated composite measure of baseline disease burden. The authors also align themselves with earlier correspondents, Talari and Goyal, who noted that retrospective designs cannot establish causality. Their own manuscript, they emphasize, explicitly frames the findings as associations rather than causal effects. This is a crucial framing for readers: the study does not claim that narcolepsy itself causes death, but that in real-world clinical practice, patients diagnosed and managed for narcolepsy died at higher rates than comparable sleep clinic patients, even when those comparators carried a substantially heavier comorbidity burden at baseline.

The reliability of the mortality outcome itself became another point of contention, and here the authors marshal quantitative evidence. Vital status data in the Veterans Health Administration have been independently validated against the National Death Index, the United States’ authoritative repository of death records. That validation work, published by Sohn and colleagues, found a sensitivity of 98.3 percent and exact-date agreement of 97.6 percent, figures that support the accuracy and completeness of the VHA’s mortality ascertainment. In practical terms, this means the study’s primary endpoint, all-cause death, was measured against a benchmark that few national datasets can match. The authors argue that these psychometric properties of the data source underpin the reliability of their central finding, whatever reservations may attach to the diagnostic classification of the exposure.

That diagnostic classification was the critics’ most technically substantive objection. Definitive diagnosis of narcolepsy type 1 under the International Classification of Sleep Disorders, third edition, requires objective confirmation: polysomnography followed by a multiple sleep latency test demonstrating shortened sleep latency and early REM onset, or cerebrospinal fluid measurement revealing low hypocretin-1, the neuropeptide whose loss underlies the disorder’s pathophysiology. The critics asked how many participants had cataplexy and whether all had undergone these tests. The authors’ answer is a candid acknowledgment of the limits of administrative data: polysomnography and multiple sleep latency test results are not captured in a standardized format across the national VHA dataset, and cerebrospinal fluid hypocretin testing is rarely performed in routine Veterans Affairs practice. These data simply cannot be ascertained reliably from administrative records, a constraint that shaped the study’s entire design philosophy.

Rather than attempting an unattainable gold-standard confirmation, the researchers employed a computable phenotyping algorithm, requiring at least two narcolepsy diagnosis codes separated by 30 to 390 days. This temporal separation requirement is designed to improve diagnostic specificity by filtering out random or provisional miscoding, since a genuine narcolepsy diagnosis tends to persist across multiple encounters while a coding error is less likely to be repeated weeks or months later. The authors note that this approach aligns with prior large electronic health record based studies of narcolepsy. They also push back on the implicit assumption that the diagnostic gold standard is itself flawless, citing work by Trotti and colleagues showing that approximately half of patients with noncataplectic central hypersomnia received a different diagnosis when the multiple sleep latency test was repeated. Even in tertiary referral settings, the boundary between narcolepsy type 2 and idiopathic hypersomnia is unstable, which complicates any demand for perfect phenotypic precision.

The critics also raised the specter of confounding by conditions and medications that mimic or modify hypersomnolence: endocrine disorders such as hypothyroidism, and drug classes including antiepileptics, analgesics, antihistamines, and immunosuppressants. The authors offer a reasoned rebuttal on both fronts. Hypothyroidism and similar conditions, they argue, would more plausibly be misclassified within the general sleep clinic comparator group than within the narcolepsy cohort, where the two-code requirement reduces the likelihood of diagnostic confusion. As for the medication classes, none has a well-established direct effect on the mortality pathways most likely operative in narcolepsy, namely cardiovascular events and accident-related deaths, and adding them would have introduced collinearity without addressing the principal causal hypotheses. The study instead focused on comorbidity groups with established relevance to mortality risk in narcolepsy: cardiovascular, metabolic, pulmonary, neurologic, and psychiatric conditions. The authors caution that expanding the model to every conceivable confounder would reduce interpretability, destabilize the statistical models, and exceed the constraints of available structured data.

The exchange is a window into a broader tension in modern epidemiology. Big data cohorts built from electronic health records offer scale, duration, and real-world generalizability that carefully phenotyped prospective studies cannot match, but they sacrifice diagnostic granularity in return. The authors of the reply do not dispute that prospectively defined cohorts are essential for answering mechanistic questions and refining diagnostic precision; they simply note that such cohorts are logistically difficult to obtain for rare disorders and cannot provide the scale or quarter-century of follow-up available in the VHA population. Their study, they reiterate, was never designed to establish causality or to revalidate diagnostic criteria, but to assess whether narcolepsy, as diagnosed and managed in ordinary clinical practice, is associated with increased mortality and healthcare utilization. On that question, they argue, the answer stands: the elevated mortality persisted even against a comparator group with a higher baseline comorbidity burden, reinforcing the clinical relevance of the finding and the case that real-world evidence, carefully constructed, deserves a seat at the table in rare-disease research.

Subject of Research: Mortality risk and study methodology in narcolepsy research using large electronic health record cohorts

Article Title: Reply to “The question of whether narcolepsy increases mortality should be answered based on reliable studies”

Article References: Sharafkhaneh, A., BaHammam, A. S., Dauvilliers, Y., Azarian, M., Thorpy, M., Han, F., Senel, G. B., Aksu, M., & Razjouyan, J. (2026). Reply to “The question of whether narcolepsy increases mortality should be answered based on reliable studies”. Journal of Clinical Sleep Medicine, 22(1), Article 110. https://doi.org/10.1007/s44470-026-00121-8

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00121-8

Keywords: narcolepsy, mortality, electronic health records, retrospective cohort study, propensity score matching, Veterans Health Administration, sleep medicine, computable phenotyping, polysomnography, multiple sleep latency test, confounding, hypocretin